Latest News
-
Thursday - September 16, 2021
Launch of Bayer Science Collaboration Explorer:
Bayer launches transparency register for scientific collaborations with external partners
Open access database makes new contract-based scientific collaborations with universities, public research institutions and individuals publicly available in Germany » more
-
Thursday - September 16, 2021
Not intended for U.S. and UK Media – ESMO Congress 2021:
Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer
In an updated analysis on the adult subset of non-central nervous system (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3 months was observed as well as an extended progression-free survival (PFS; median of 25.8 months) as assessed by investigators / Post hoc sub-analysis of investigator-assessed ORR, DoR and PFS of patients (n=218) show uniformly high ORRs in patients regardless of prior treatment or performance status; highest response rates observed in patients receiving first-line larotrectinib (81%) and being Eastern Cooperative Oncology Group performance status (ECOG PS) 0 (85%) / Safety profile for larotrectinib continues to be consistent with that previously published; analysis on the incidence of fractures in larotrectinib trials shows no fracture related to larotrectinib based on investigator assessment / E-Poster published of a matching-adjusted indirect comparison (MAIC) evaluating efficacy (overall survival [OS], PFS, ORR including complete responses and DoR) and safety observed in clinical trials with larotrectinib compared to entrectinib. MAIC is an alternative method for comparative data when a head-to-head randomized control trial (RCT) is not available and/or possible, like for TRK fusion cancer which is an ultra-rare disease » more
-
Tuesday - September 14, 2021
Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures
Andes has developed novel seed treatment technology that allows crops to thrive without synthetic fertilizers / Funds will aid the development of revolutionary nature-based carbon capture technology » more
-
Thursday - September 9, 2021
SVG Ventures | THRIVE and Bayer Announce their Sustainability Challenge Winners
Winners chosen from a global pool of around 300 applicants from across 57 countries » more
-
Thursday - September 9, 2021
Not intended for U.S. and UK Media
Bayer to highlight expanded research from growing oncology portfolio at ESMO Congress 2021
Updated analyses for Vitrakvi™ (larotrectinib) reaffirm sustained clinical benefits for patients with TRK fusion cancer / Breadth of prostate cancer portfolio on display, including presentations for Nubeqa™ (darolutamide) in non-metastatic castration-resistant prostate cancer (nmCRPC), and Xofigo™ (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) / Oral presentation on analysis from CHRONOS-3 study evaluating Aliqopa™ (copanlisib) plus rituximab in patients with marginal zone lymphoma (MZL) / Ongoing investigator-initiated research featuring StivargaTM (regorafenib) in various indications and difficult-to-treat tumors » more
-
Monday - September 6, 2021
Not intended for U.S. and UK Media
Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
Significant improvement in 24-hour cough counts over placebo after 12 weeks of treatment and with a favorable safety and tolerability profile / Results from PAGANINI Phase IIb dose-finding study presented at the virtual European Respiratory Society (ERS) International Congress 2021 / Currently no treatment approved for refractory chronic cough, a condition affecting one to five percent of people wordwide » more
- ARCHIVIERT
Tuesday - August 31, 2021
Not intended for U.S. and UK Media
Bayer starts Phase III clinical development program OASIS with Elinzanetant
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause » more
-
Saturday - August 28, 2021
Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021
New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression » more
-
Tuesday - August 24, 2021
Not intended for U.S. and UK Media
U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin
Patients after recent lower-extremity revascularization due to symptomatic PAD now included in the label in the US / Xarelto plus aspirin is the first treatment approach indicated in the US for both coronary artery disease (CAD) and PAD, now including patients post recent lower-extremity revascularization (LER) due to symptomatic PAD » more
-
Thursday - August 19, 2021
Leaps by Bayer Leads USD 45 Million Financing in Sound Agriculture to Accelerate Sustainability Solutions for Food and Agriculture
Sound’s Dual-Technology Platform Uses Biochemistry to Tap into the Natural Capabilities of the Plant to Increase the Speed and Efficiency of Agriculture » more
-
Tuesday - August 17, 2021
Not intended for U.S. and UK Media – ESC Congress 2021 – The Digital Experience:
Bayer to present data from cardiovascular portfolio, including late breaking data from Phase III FIGARO-DKD (finerenone) and various Xarelto™ studies
Detailed results from the FIGARO-DKD study will be presented, which investigated the efficacy and safety of finerenone regarding cardiovascular and kidney outcomes versus placebo in addition to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / Data for finerenone from FIDELITY, a prespecified integrated analysis of FIDELIO-DKD and FIGARO-DKD which together formed the largest Phase III study program to date in CKD and T2D, will be presented / New rivaroxaban (Xarelto™) data from the VOYAGER PAD study in patients with peripheral artery disease and ANTENNA, EMIR and AFIRE studies in patients who have atrial fibrillation / Further data from the Phase III VICTORIA trial provides new insights into use of vericiguat (Verquvo™), including those receiving an angiotensin receptor neprilysin inhibitor (ARNI) / For the first time, worsening heart failure has been explicitly recognized in an update to the European Society of Cardiology (ESC) Guidelines for Acute and Chronic Heart Failure » more
-
Monday - August 16, 2021
Bayer announces filing of petition to U.S. Supreme Court for review of Hardeman decision
Company argues errors on federal preemption and expert evidence standards necessitate review of rulings / Decision could affect thousands of Roundup™ cases and other litigation » more
-
Thursday - August 5, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need / Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas / Vividion to operate autonomously and on an arm’s length basis / Purchase price of USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments » more
-
Thursday - August 5, 2021
Second quarter of 2021
Bayer: Strong growth, guidance upgrade
Group sales increase by 12.9 percent (Fx & portfolio adj.) to 10.854 billion euros – double-digit percentage growth (Fx & portfolio adj.) at all divisions / EBITDA before special items declines by 10.6 percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3 percent to 1.61 euros / Net income at minus 2.335 billion euros, additional provisions of around 3.5 billion euros established for glyphosate litigations / Strong free cash flow of 1.152 billion euros / Full-year guidance upgraded / Good pipeline news: Kerendia™ gains U.S. approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment » more
-
Tuesday - August 3, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
Positive Phase IIb results for eliapixant in patients with refractory chronic cough » more
-
Monday - August 2, 2021
Bayer selects 100 youth leaders from around the world to help “Feed a Hungry Planet” at the company’s 5th biennial Youth Ag Summit
The 100 delegates representing over 40 countries will meet in November 2021 for a virtual global forum / Delegates will also work with the UN Sustainable Development Solutions Network (SDSN) and Babele on a 10-week Youth Ag Summit (YAS) University program following the forum with mentoring from industry leaders, farmers, and YAS alumni » more
-
Thursday - July 29, 2021
Bayer Provides Update on Path to Closure of Roundup™ Litigation » more
-
Monday - July 26, 2021
BlueRock Therapeutics Announces New Board Chair, New President and CEO » more
-
Monday - July 26, 2021
Bayer announces Prof. Dr. Dominik Ruettinger as new Head of Research and Early Development for Oncology » more
-
Wednesday - July 21, 2021
Bayer Reinforces Commitment to Increasing Fruit and Vegetable Consumption
Commitment to promoting increased fruit and vegetable consumption key to Bayer’s vision of ‘Health for All, Hunger for None’ / Portfolio innovations and Field-to-Fork Horticulture strategy put digital transformation and innovation at the core of Bayer’s fruit and vegetable offerings / Bayer is now a participating member of the Sustainability Initiative for Fruits and Vegetables (SIFAV) » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, November 9, 2021
Q3 2021 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV